PDL BioPharma, Inc.
PDL BIOPHARMA, INC. (Form: 8-K, Received: 03/14/2017 06:03:02)


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 14, 2017

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 








Item 7.01 Other Events.
 
On March 14, 2017, PDL BioPharma, Inc. (the Company) will make presentations and participate in conferences with investors and analysts in connection with the 29 th Annual ROTH Conference in Dana Point, California. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2017. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 
Presentation






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ John P. McLaughlin
 
 
John P. McLaughlin
 
 
President and Chief Executive Officer




Dated: March 14, 2017






Exhibit Index


Exhibit No.
 
Description
99.1
 
Presentation





Exhibit 99.1

SLIDE1A37.JPG





SLIDE2A37.JPG





SLIDE3A37.JPG





SLIDE4A37.JPG





SLIDE5A37.JPG





SLIDE6A37.JPG





SLIDE7A37.JPG





SLIDE8A35.JPG





SLIDE9A33.JPG





SLIDJ16.JPG





SLIDJ17.JPG





SLIDJ18.JPG





SLIDJ19.JPG





SLIDJ20.JPG





SLIDJ21.JPG





SLIDJ22.JPG





SLIDJ23.JPG





SLIDJ24.JPG





SLIDJ25.JPG





SLIDJ26.JPG





SLIDJ27.JPG





SLIDJ28.JPG





SLIDJ29.JPG





SLIDJ30.JPG





SLIDJ31.JPG





SLIDJ32.JPG





SLIDJ33.JPG





SLIDJ34.JPG





SLIDJ35.JPG





SLIDJ36.JPG





SLIDJ37.JPG





SLIDJ38.JPG





SLIDJ39.JPG





SLIDJ40.JPG





SLIDJ41.JPG





SLIDJ42.JPG





SLIDJ43.JPG





SLIDJ44.JPG





SLIDJ45.JPG





SLIDJ46.JPG





SLIDJ47.JPG





SLIDJ48.JPG





SLIDJ49.JPG





SLIDJ50.JPG





SLIDJ51.JPG





SLIDJ52.JPG





SLIDJ53.JPG





SLIDJ54.JPG





SLIDJ55.JPG





SLIDJ56.JPG